Live Cell in Vitro and in Vivo Imaging Applications: Accelerating Drug Discovery

Pharmaceutics

Beverley Isherwood²  Paul Timpson¹  Ewan J McGhee¹  Kurt I Anderson¹  Marta Canel³  Alan Serrels³  Valerie G Brunton³ 

[1]Beatson Institute for Cancer Research, Garscube Estate, Glasgow G61 1BD, UK

[2] E-Mails:

[3]Advanced Science & Technology Laboratory, AstraZeneca R&D Charnwood, Loughborough LE11 5RH, UK

[4] E-Mail:

[5]Edinburgh Cancer Research UK Centre, Institute of Genetics and Molecular Medicine, University of Edinburgh, Crewe Road South, Edinburgh, EH4 2XR, UK

[6] E-Mails:

关键词: imaging;    intravital;    high-content;    temporal;    fluorescence;    drug discovery;    biomarkers;    translation;    efficacy;   

DOI  :  10.3390/pharmaceutics3020141

来源: mdpi

【 摘 要 】

Dynamic regulation of specific molecular processes and cellular phenotypes in live cell systems reveal unique insights into cell fate and drug pharmacology that are not gained from traditional fixed endpoint assays. Recent advances in microscopic imaging platform technology combined with the development of novel optical biosensors and sophisticated image analysis solutions have increased the scope of live cell imaging applications in drug discovery. We highlight recent literature examples where live cell imaging has uncovered novel insight into biological mechanism or drug mode-of-action. We survey distinct types of optical biosensors and associated analytical methods for monitoring molecular dynamics, in vitro and in vivo. We describe the recent expansion of live cell imaging into automated target validation and drug screening activities through the development of dedicated brightfield and fluorescence kinetic imaging platforms. We provide specific examples of how temporal profiling of phenotypic response signatures using such kinetic imaging platforms can increase the value of in vitro high-content screening. Finally, we offer a prospective view of how further application and development of live cell imaging technology and reagents can accelerate preclinical lead optimization cycles and enhance the in vitro to in vivo translation of drug candidates.

【 授权许可】

CC BY   
© 2011 by the authors; licensee MDPI, Basel, Switzerland.